Biocytogen

Animal Models and Cell Lines

>Double Humanized Immune-Checkpoint Mice

B-hPD-1/hTIM3 mice


Basic characteristics

 

1.png


Targeting strategy


image.png


Protein expression analysis

 

1.png

Fig 1. Splenocytes from both wild type (WT) C57BL/6 and homozygous B-hPD-1/hTIM3 mice were analyzed by flow cytometry. Mouse TIM3+ T cells were detectable in the WT C57BL/6 mice, while human TIM3+ T cells were detectable in the homozygous B-hPD-1/hTIM3 mice.

 2.png 

Fig 2.  Splenocytes from both wild type (WT) C57BL/6 and homozygous B-hPD-1/hTIM3 mice were analyzed by flow cytometry. Mouse PD-1+ T cells were detectable in the WT C57BL/6 mice, while human PD-1+ T cells were detectable in the homozygous B-hPD-1/hTIM3 mice.


Combination Therapy of PD-1 mAb (keytruda) and TIM3 mAb (Mc38 cell line)


 image.png


Fig 3. Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hPD-1/hTIM3 mice. Mice were grouped when the tumor size was approximately 150±50 mm3 (n=6). Anti-TIM3 antibody and the anti-hPD-1 antibody Keytruda shows obviously inhibitory effects respectively. Combination of anti-hTIM3 antibody and the anti-hPD-1 antibody Keytruda shows better inhibitory effects than single treatment, suggesting that B-hPD-1/hTIM3 mouse is a powerful tool for in vivo evaluating combination therapy efficacy of hPD-1 antibody and hTIM3 antibody.


【Return list】
* Contact Name
* Quantity
Telephone No.
Email
* Shipping address
Verification code captcha
© 2018 Beijing Biocytogen Co., Ltd. All rights reserved. Technical support: fast help cloud